Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study

Abstract Although the association between apolipoprotein E (APOE) genotype and disease progression is well characterized in patients with Alzheimer’s disease, such a relationship is unknown in patients with subcortical vascular cognitive impairment. We evaluated whether APOE genotype is associated w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yeo Jin Kim, Sang Won Seo, Seong Beom Park, Jin Ju Yang, Jin San Lee, Juyoun Lee, Young Kyoung Jang, Sung Tae Kim, Kyung-Han Lee, Jong Min Lee, Jae-Hong Lee, Jae Seung Kim, Duk L. Na, Hee Jin Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5c4ad772c0a44db09bc1dc28574a4527
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c4ad772c0a44db09bc1dc28574a4527
record_format	dspace
spelling	oai:doaj.org-article:5c4ad772c0a44db09bc1dc28574a45272021-12-02T16:06:42ZProtective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study10.1038/s41598-017-02046-y2045-2322https://doaj.org/article/5c4ad772c0a44db09bc1dc28574a45272017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02046-yhttps://doaj.org/toc/2045-2322Abstract Although the association between apolipoprotein E (APOE) genotype and disease progression is well characterized in patients with Alzheimer’s disease, such a relationship is unknown in patients with subcortical vascular cognitive impairment. We evaluated whether APOE genotype is associated with disease progression in subcortical vascular mild cognitive impairment (svMCI) patients. We prospectively recruited 72 svMCI patients (19 APOE4 carriers, 42 APOE3 homozygotes, and 11 APOE2 carriers). Patients were annually followed-up with brain MRI and neuropsychological tests for three years and underwent a second Pittsburgh compound B (PiB)-PET at a mean interval of 32.3 months. Amyloid-ß burden was quantified by PiB standardized uptake value ratio (SUVR), and the amount of small vessel disease was quantified by number of lacune and small vessel disease score on MRI. We also measured cortical thickness. During the three years of follow-up, compared to the APOE3 homozygotes, there was less increase in PiB SUVR among APOE2 carriers (p = 0.023), while the APOE genotype did not show significant effects on small vessel disease progression. APOE2 carriers also showed less cortical thinning (p = 0.023) and a slower rate of cognitive decline (p = 0.009) compared to those with APOE3 homozygotes. Our findings suggest that, in svMCI patients, APOE2 has protective effects against amyloid-ß accumulation, cortical thinning, and cognitive decline.Yeo Jin KimSang Won SeoSeong Beom ParkJin Ju YangJin San LeeJuyoun LeeYoung Kyoung JangSung Tae KimKyung-Han LeeJong Min LeeJae-Hong LeeJae Seung KimDuk L. NaHee Jin KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yeo Jin Kim Sang Won Seo Seong Beom Park Jin Ju Yang Jin San Lee Juyoun Lee Young Kyoung Jang Sung Tae Kim Kyung-Han Lee Jong Min Lee Jae-Hong Lee Jae Seung Kim Duk L. Na Hee Jin Kim Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
description	Abstract Although the association between apolipoprotein E (APOE) genotype and disease progression is well characterized in patients with Alzheimer’s disease, such a relationship is unknown in patients with subcortical vascular cognitive impairment. We evaluated whether APOE genotype is associated with disease progression in subcortical vascular mild cognitive impairment (svMCI) patients. We prospectively recruited 72 svMCI patients (19 APOE4 carriers, 42 APOE3 homozygotes, and 11 APOE2 carriers). Patients were annually followed-up with brain MRI and neuropsychological tests for three years and underwent a second Pittsburgh compound B (PiB)-PET at a mean interval of 32.3 months. Amyloid-ß burden was quantified by PiB standardized uptake value ratio (SUVR), and the amount of small vessel disease was quantified by number of lacune and small vessel disease score on MRI. We also measured cortical thickness. During the three years of follow-up, compared to the APOE3 homozygotes, there was less increase in PiB SUVR among APOE2 carriers (p = 0.023), while the APOE genotype did not show significant effects on small vessel disease progression. APOE2 carriers also showed less cortical thinning (p = 0.023) and a slower rate of cognitive decline (p = 0.009) compared to those with APOE3 homozygotes. Our findings suggest that, in svMCI patients, APOE2 has protective effects against amyloid-ß accumulation, cortical thinning, and cognitive decline.
format	article
author	Yeo Jin Kim Sang Won Seo Seong Beom Park Jin Ju Yang Jin San Lee Juyoun Lee Young Kyoung Jang Sung Tae Kim Kyung-Han Lee Jong Min Lee Jae-Hong Lee Jae Seung Kim Duk L. Na Hee Jin Kim
author_facet	Yeo Jin Kim Sang Won Seo Seong Beom Park Jin Ju Yang Jin San Lee Juyoun Lee Young Kyoung Jang Sung Tae Kim Kyung-Han Lee Jong Min Lee Jae-Hong Lee Jae Seung Kim Duk L. Na Hee Jin Kim
author_sort	Yeo Jin Kim
title	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
title_short	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
title_full	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
title_fullStr	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
title_full_unstemmed	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
title_sort	protective effects of apoe e2 against disease progression in subcortical vascular mild cognitive impairment patients: a three-year longitudinal study
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/5c4ad772c0a44db09bc1dc28574a4527
work_keys_str_mv	AT yeojinkim protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT sangwonseo protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT seongbeompark protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT jinjuyang protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT jinsanlee protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT juyounlee protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT youngkyoungjang protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT sungtaekim protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT kyunghanlee protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT jongminlee protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT jaehonglee protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT jaeseungkim protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT duklna protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy AT heejinkim protectiveeffectsofapoee2againstdiseaseprogressioninsubcorticalvascularmildcognitiveimpairmentpatientsathreeyearlongitudinalstudy
_version_	1718384903915044864

Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study

Ejemplares similares